Jiangsu Jibeier Pharmaceutical (SH:688566)2026-02-27 09:05Financial Performance - Total operating revenue for 2025 reached ¥964,930,489.25, an increase of 7.63% year-on-year[2] - Net profit attributable to shareholders of the parent company was ¥258,668,187.82, up 17.94% compared to the previous year[2] - Basic earnings per share rose to ¥1.30, representing a 15.04% increase from ¥1.13 in the previous year[2] - The weighted average return on net assets increased by 0.53 percentage points to 11.04%[2] Assets and Equity - Total assets at the end of the reporting period were ¥2,709,928,593.09, reflecting a 7.22% increase from the beginning of the period[5] - Shareholders' equity attributable to the parent company increased by 7.94% to ¥2,427,107,981.56[5] Drug Development - The company is advancing the development of new drugs, including JJH201501 for depression and JJH201601 for oncology, with clinical trials progressing[5] Incentive Plans - The company implemented a restricted stock incentive plan for 2025, with share-based payment expenses amounting to ¥23,506,400 (unaudited)[5] Risk Awareness - The company emphasizes the importance of risk awareness, noting that the financial data is preliminary and subject to audit[6] Operational Performance - The company continues to strengthen team building and market development, contributing to overall positive operational performance[5]